Pereira Lab researcher Camila Vazquez Echegaray was awarded a Marie Skłodowska-Curie Actions (MSCA) Postdoctoral Fellowship.

The Pereira Lab took part in a meeting held by Asgard Therapeutics AB, together with consortium members InSphero and Antineo, that sets the official kick-off to the earlier announced Eurostars project.

PU.1, IRF8, and BATF3 cooperation and role in inflammatory signaling during programming of human cDC1-like cells was uncovered at the Pereira Lab.

Asgard Therapeutics AB, a private biotech company spin off from the Pereira Lab, announces the completion of a EUR 6 million seed financing round. The financing was co-led by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.

On June 10th 2021, Fábio Rosa defended his thesis “Generating Dendritic Cells by Direct Cell Reprogramming. Merging cellular reprogramming with immunology towards the development of novel cancer immunotherapies.” with Prof. Thomas Graf from the Center for Genomic Regulation (Spain) as opponent.

Following on the legacy of Professor Sir Ian Wilmut, Filipe Pereira becomes the new Editor-in-Chief of the Cellular Reprogramming Journal.

The Swedish Research Council (Vetenskapsrådet) has published the results for this year’s applications for consolidator grants, in which Filipe Pereira was selected for, in the scientific area of Medicine and health.

Pereira Lab researcher Luís Oliveira was awarded a fully funded 4 year scholarship by the Portuguese Foundation for Science and Technology (FCT) to develop his PhD-leading research.

The Pereira Lab has been awarded a grant from the Mats Paulsson Foundation for Research, Innovation and Societal Development on a project aiming at Harnessing Dendritic Cell Reprogramming for Cancer Immunotherapy.

Filipe Pereira was recently awarded with the KiiLN Postdoctoral Entrepreneurship Award by the Keystone for Incubating Innovation in Life Sciences Network at the Icahn School of Medicine Innovation Awards.